1.The Process of Mesenchymal Stem Cells and their Potential as Cardiac Therapeutics
Shu-Kuan LING ; Ying-Hui LI ; Zhong-Quan DAI ; Fen YANG ; Jie-Lin NIE ;
China Biotechnology 2006;0(06):-
Bone marrow mesenchymal stem cells (MSCs), multipotent stem cells, can replicate as undifferentiated cells and have the potential to differentiate into different lineages of mesenchymal tissues, including bone, cartilage,endothelial, neural, smooth muscle, skeletal myoblasts, and cardiac myocyte cells. The ischemia-induced death of cardiomyocytes results in scar formation and reduced contractility of the ventricle. Several preclinical and clinical studies have supported the notion that MSCs therapy may be used for cardiac regeneration.When transplanted into the infracted heart, MSCs prevent deleterious remodeling and improve recovery, but the mechanism is not clear. In this work,we review evidence and new prospects that support the use of MSCs in cardiomyoplasty.
2.Mechanism of cardiac atrophy under weightlessness/simulated weightlessness.
Guo-Hui ZHONG ; Shu-Kuan LING ; Ying-Xian LI
Acta Physiologica Sinica 2016;68(2):194-200
Cardiac remodeling is the heart's response to external or internal stimuli. Weightlessness/simulated weightlessness leads to cardiac atrophy and heart function declining. Understanding the mechanism of cardiac atrophy under weightlessness is important to help astronaut recover from unloading-induced cardiovascular changes after spaceflight. Unloading-induced changes of hemodynamics, metabolic demands and neurohumoral regulation contribute to cardiac atrophy and function declining. During this process, Ca(2+)-related signaling, NF-κB signaling, ERK signaling, ubiquitin-proteasome pathway and autophagy are involved in weightlessness-induced cardiac atrophy. This article reviews the underlying mechanism of cardiac atrophy under weightlessness/simulated weightlessness.
Atrophy
;
Heart
;
Heart Diseases
;
Hemodynamics
;
Humans
;
NF-kappa B
;
Space Flight
;
Weightlessness
;
Weightlessness Simulation
3.Efficacy and influencing factors of allogeneic hematopoietic stem cell transplantation in treatment of 71 children with leukemia.
Bing-Lei ZHANG ; Jian ZHOU ; Tian-Xi LYU ; Rui-Rui GUI ; Ying-Ling ZU ; Feng-Kuan YU ; Hui-Fang ZHAO ; Zhen LI ; Juan WANG ; Yan-Li ZHANG ; Wen-Lin ZHANG ; Yue-Wen FU ; Xu-Dong WEI ; Bai-Jun FANG ; Yu-Fu LI ; Ke-Shu ZHOU ; Yong-Ping SONG
Chinese Medical Journal 2019;132(7):860-864
Adolescent
;
Busulfan
;
therapeutic use
;
Child
;
Child, Preschool
;
Cyclophosphamide
;
therapeutic use
;
Cyclosporine
;
therapeutic use
;
Female
;
Hematopoietic Stem Cell Transplantation
;
methods
;
Humans
;
Infant
;
Leukemia
;
drug therapy
;
mortality
;
therapy
;
Leukemia, Myeloid, Acute
;
drug therapy
;
mortality
;
therapy
;
Male
;
Mycophenolic Acid
;
therapeutic use
;
Precursor Cell Lymphoblastic Leukemia-Lymphoma
;
drug therapy
;
mortality
;
therapy
;
Retrospective Studies
;
Treatment Outcome
4.Components of drugs in acupoint sticking therapy and its mechanism of intervention on bronchial asthma based on UPLC-Q-TOF-MS combined with network pharmacology and experimental verification.
Jun HU ; Ling WENG ; Cong ZHANG ; Shu-Mei ZHAO ; Kai-Wen GE ; Kuan DI ; Meng CAO ; He-Sheng WANG ; Lin-Gang ZHAO ; Lan-Ying LIU
China Journal of Chinese Materia Medica 2022;47(5):1359-1369
UPLC-Q-TOF-MS combined with network pharmacology and experimental verification was used to explore the mechanism of acupoint sticking therapy(AST) in the intervention of bronchial asthma(BA). The chemical components of Sinapis Semen, Cory-dalis Rhizoma, Kansui Radix, Asari Radix et Rhizoma, and Zingiberis Rhizoma Recens were retrieved from TCMSP as self-built database. The active components in AST drugs were analyzed by UPLC-Q-TOF-MS, and the targets were screened out in TCMSP and Swiss-TargetPrediction. Targets of BA were collected from GeneCards, and the intersection of active components and targets was obtained by Venny 2.1.0. The potential targets were imported into STRING and DAVID for PPI, GO, and KEGG analyses. The asthma model induced by house dust mite(HDM) was established in mice. The mechanism of AST on asthmatic mice was explored by pulmonary function, Western blot, and flow cytometry. The results indicated that 54 active components were obtained by UPLC-Q-TOF-MS and 162 potential targets were obtained from the intersection. The first 53 targets were selected as key targets. PPI, GO, and KEGG analyses showed that AST presumedly acted on SRC, PIK3 CA, and other targets through active components such as sinoacutine, sinapic acid, dihydrocapsaicin, and 6-gingerol and regulated PI3 K-AKT, ErbB, chemokine, sphingolipid, and other signaling pathways to intervene in the pathological mechanism of BA. AST can improve lung function, down-regulate the expression of PI3 K and p-AKT proteins in lung tissues, enhance the expression of PETN protein, and reduce the level of type Ⅱ innate immune cells(ILC2 s) in lung tissues of asthmatic mice. In conclusion, AST may inhibit ILC2 s by down-regulating the PI3 K-AKT pathway to relieve asthmatic airway inflammation and reduce airway hyperresponsiveness.
Acupuncture Points
;
Animals
;
Asthma/drug therapy*
;
Drugs, Chinese Herbal
;
Immunity, Innate
;
Lymphocytes
;
Mice
;
Network Pharmacology
5.Expert consensus statement on Kangfu Xiaoyan Suppository in treatment of pelvic inflammatory in clinical practice.
Lian-Xin WANG ; Li-Hui HOU ; Yan-Ming XIE ; Kun MA ; Su-Lun SUN ; Zhe JIN ; Hui-Lan DU ; Dong-Mei WANG ; Hong ZHAO ; Yan-Feng LIU ; Ling TANG ; Kuan-Yong SHU ; Cui-Zhen ZHANG ; Wei SHI ; Si-Yan ZHAN ; Jian-Ping LIU ; Wei CHEN ; Yao-Long CHEN
China Journal of Chinese Materia Medica 2019;44(20):4350-4353
Kangfu Xiaoyan Suppository is widely used in the treatment of gynecological inflammatory diseases. Long-term clinical application and a certain amount of research evidences show that Kangfu Xiaoyan Suppository can alleviate the clinical symptoms of pelvic inflammatory diseases,reduce the recurrence rate,and relieve sequelae,with a better safety and economic characteristics. As a type of nationally protected traditional Chinese medicine and type B medicine included in medical insurance,it has been selected as a Chinese patent medicine for rectal administration. It was included in the Guidelines for diagnosis and treatment of common gynecological diseases of traditional Chinese medicine published by the Chinese Academy of Traditional Chinese Medicine in 2012,the Pelvic inflammatory diseases diagnosis and treatment guidelines issued by the Infectious Diseases Collaborative Group of the Obstetrics and Gynecology Branch of the Chinese Medical Association in 2014,and the group standard of Single use of traditional Chinese medicine/combined antibiot guidelines for clinical practice-pelvic inflammatory diseases of the Chinese Academy of Traditional Chinese Medicine in 2017. To further enhance clinicians' understanding of the drug and better guide its rational clinical use,experts from the field of gynecology of traditional Chinese and Western medicine were invited to develop and compile this expert consensus. This consensus takes full account of clinical evidences and expert clinical experience,and form recommendations for clinical problems based on evidences and consensus recommendations for clinical problems without evidence by nominal grouping method. The expert consensus is mainly formed in the consideration of six factors: quality of evidence,economy,efficacy,adverse reactions,patient acceptability and others. Based on clinical research evidences and expert experience,this consensus provides a preliminary reference for the clinical use of the drug in a concise and clear format. However,evidence-based support is still required in a large number of high-quality studies,and this consensus will be revised in the future according to new clinical problems and the update of evidence-based evidence in practical application.
Consensus
;
Drugs, Chinese Herbal/therapeutic use*
;
Female
;
Humans
;
Medicine, Chinese Traditional
;
Nonprescription Drugs
;
Pelvic Inflammatory Disease/drug therapy*
;
Suppositories